BR112015030350B1 - Forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular - Google Patents

Forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular Download PDF

Info

Publication number
BR112015030350B1
BR112015030350B1 BR112015030350-1A BR112015030350A BR112015030350B1 BR 112015030350 B1 BR112015030350 B1 BR 112015030350B1 BR 112015030350 A BR112015030350 A BR 112015030350A BR 112015030350 B1 BR112015030350 B1 BR 112015030350B1
Authority
BR
Brazil
Prior art keywords
dosage form
coating
acetylsalicylic acid
pharmaceutical dosage
form according
Prior art date
Application number
BR112015030350-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015030350A2 (pt
Inventor
Pablo MARTIN SANZ
Javier URBANO HURTADO
Original Assignee
Ferrer Internacional, S.A.
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015030350(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Internacional, S.A., Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii filed Critical Ferrer Internacional, S.A.
Publication of BR112015030350A2 publication Critical patent/BR112015030350A2/pt
Publication of BR112015030350B1 publication Critical patent/BR112015030350B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112015030350-1A 2013-06-06 2014-06-05 Forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular BR112015030350B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases
EP13170909.9 2013-06-06
PCT/EP2014/061735 WO2014195421A1 (en) 2013-06-06 2014-06-05 Oral formulation for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
BR112015030350A2 BR112015030350A2 (pt) 2017-07-25
BR112015030350B1 true BR112015030350B1 (pt) 2022-11-29

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030350-1A BR112015030350B1 (pt) 2013-06-06 2014-06-05 Forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular

Country Status (42)

Country Link
US (1) US10617699B2 (https=)
EP (3) EP2810644A1 (https=)
JP (1) JP6151854B2 (https=)
KR (1) KR101839665B1 (https=)
CN (2) CN113143888A (https=)
AP (1) AP2015008882A0 (https=)
AR (1) AR096350A1 (https=)
AU (1) AU2014276883B2 (https=)
BR (1) BR112015030350B1 (https=)
CA (1) CA2912350C (https=)
CL (1) CL2015003561A1 (https=)
CR (1) CR20150635A (https=)
CU (1) CU24326B1 (https=)
CY (1) CY1118766T1 (https=)
DK (1) DK2986281T3 (https=)
DO (1) DOP2015000296A (https=)
EA (1) EA028969B1 (https=)
EC (1) ECSP15050273A (https=)
ES (1) ES2620078T3 (https=)
GE (1) GEP201706743B (https=)
HK (1) HK1204562A1 (https=)
HU (1) HUE033458T2 (https=)
IL (1) IL242569B (https=)
MA (1) MA38699B1 (https=)
MD (1) MD4475C1 (https=)
MX (1) MX347801B (https=)
MY (1) MY181272A (https=)
NI (1) NI201500171A (https=)
NZ (1) NZ714707A (https=)
PE (1) PE20160051A1 (https=)
PH (1) PH12015502706A1 (https=)
PL (1) PL2986281T3 (https=)
PT (1) PT2986281T (https=)
RS (1) RS55786B1 (https=)
SA (1) SA515370243B1 (https=)
SG (1) SG11201509353QA (https=)
SI (1) SI2986281T1 (https=)
TN (1) TN2015000501A1 (https=)
TW (1) TWI630928B (https=)
UA (1) UA113806C2 (https=)
WO (1) WO2014195421A1 (https=)
ZA (1) ZA201508452B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061213T2 (hu) * 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
HUE066396T2 (hu) 2022-06-30 2024-08-28 Ferrer Int Orális kapszulák, amelyek atorvasztatin tablettákat tartalmaznak, amelyek megfelelõ oldódási profilt és biológiai hozzáférhetõséget mutatnak
CO2025012256A1 (es) 2024-09-12 2026-03-16 Laboratorios Silanes S A De C V Composición farmacéutica que comprende rosuvastatina y ácido acetilsalicílico, proceso de preparación y usos de la misma

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
AU732465B2 (en) 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
KR20030025903A (ko) 2000-02-10 2003-03-29 비피에스아이 홀딩스, 인코포레이션. 아크릴 장용 코팅 조성물
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (de) 2003-03-10 2004-09-23 Bayer Healthcare Ag Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
NZ544784A (en) * 2003-07-28 2009-11-27 Reddys Lab Inc Dr Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated.
ES2395724T3 (es) 2003-08-20 2013-02-14 Shionogi & Co., Ltd. Nueva composición de recubrimiento
AU2004293178B8 (en) 2003-11-26 2009-01-08 Novartis Ag Organic compounds
EP1784193A4 (en) * 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS
WO2010127205A2 (en) * 2009-04-30 2010-11-04 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
JP2008532983A (ja) 2005-03-11 2008-08-21 シュペーデル・エクスペリメンタ・アーゲー レニン阻害剤として有用な複素環置換アルカンアミド
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
WO2009022821A2 (en) 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
RU2477123C2 (ru) * 2008-03-28 2013-03-10 Феррер Интернасионал, С.А. Капсула и лекарственное средство для профилактики сердечно-сосудистых заболеваний
CA2754134C (en) * 2009-02-11 2018-09-18 Cadila Pharmaceuticals Ltd. Stable pharmaceutical composition for atherosclerosis
KR20120130078A (ko) 2009-11-09 2012-11-28 메디비르 아베 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
MX2015015753A (es) 2016-08-03
UA113806C2 (xx) 2017-03-10
CA2912350A1 (en) 2014-12-11
MX347801B (es) 2017-05-15
CU20150173A7 (es) 2016-06-29
SI2986281T1 (sl) 2017-07-31
PL2986281T3 (pl) 2017-06-30
AU2014276883A1 (en) 2015-11-26
WO2014195421A1 (en) 2014-12-11
EP2986281A1 (en) 2016-02-24
HUE033458T2 (en) 2017-12-28
PE20160051A1 (es) 2016-01-25
TWI630928B (zh) 2018-08-01
EP2810644A1 (en) 2014-12-10
EP3175849A1 (en) 2017-06-07
RS55786B1 (sr) 2017-07-31
ECSP15050273A (es) 2017-07-31
TN2015000501A1 (en) 2017-04-06
CN104224804A (zh) 2014-12-24
MD20160001A2 (ro) 2016-05-31
CR20150635A (es) 2016-06-10
CY1118766T1 (el) 2017-07-12
NZ714707A (en) 2019-04-26
JP2016520135A (ja) 2016-07-11
SA515370243B1 (ar) 2016-09-19
EA201600012A1 (ru) 2016-07-29
HK1204562A1 (en) 2015-11-27
US10617699B2 (en) 2020-04-14
AR096350A1 (es) 2015-12-23
CN113143888A (zh) 2021-07-23
AU2014276883B2 (en) 2017-04-20
PH12015502706B1 (en) 2016-03-14
CU24326B1 (es) 2018-03-13
PH12015502706A1 (en) 2016-03-14
US20160106763A1 (en) 2016-04-21
IL242569B (en) 2018-12-31
CA2912350C (en) 2017-04-04
TW201536357A (zh) 2015-10-01
GEP201706743B (en) 2017-09-25
EA028969B1 (ru) 2018-01-31
MA38699B1 (fr) 2017-09-29
BR112015030350A2 (pt) 2017-07-25
PT2986281T (pt) 2017-03-29
DOP2015000296A (es) 2016-12-30
AP2015008882A0 (en) 2015-11-30
CL2015003561A1 (es) 2016-06-10
DK2986281T3 (en) 2017-04-03
MA38699A1 (fr) 2017-01-31
ZA201508452B (en) 2017-02-22
SG11201509353QA (en) 2015-12-30
MD4475C1 (ro) 2017-11-30
KR20160014622A (ko) 2016-02-11
MY181272A (en) 2020-12-21
KR101839665B1 (ko) 2018-03-16
NI201500171A (es) 2019-05-07
JP6151854B2 (ja) 2017-06-21
ES2620078T3 (es) 2017-06-27
EP2986281B1 (en) 2016-12-21
MD4475B1 (ro) 2017-04-30

Similar Documents

Publication Publication Date Title
AU2010315362B2 (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
MX2014002163A (es) Métodos para el tratamiento de desórdenes cardiovasculares.
BR112018001859B1 (pt) Comprimido, e, método para produzir um comprimido
JP2022501320A (ja) 抗血小板剤と胃酸分泌阻害剤を含む医薬組成物
BR112015030350B1 (pt) Forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular
JP7493048B2 (ja) 経口投与用の医薬組成物
KR102139346B1 (ko) HMG-CoA 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제
EP3377046A1 (en) Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
CN105431140B (zh) 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂
JP5232641B2 (ja) 新規なアセチルサリチル酸製剤
OA17601A (en) Oral formulation for the treatment of cardiovascular diseases.
WO2013159166A1 (pt) Forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
EP3981470A1 (en) Enteric-coated preparation comprising xanthine oxidase inhibitor
BR112014007876B1 (pt) Forma de dosagem, composição, processo para preparação de uma composição, uso de uma composição
EA045511B1 (ru) Состав с афабицином, способ его получения и его применение

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2014, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.